Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, discusses the long-term treatment of migraine with CGRP monoclonal antibodies (mAbs). Long-term safety and efficacy data show that CGRP mAbs are effective and that the number of adverse events doesn’t increase over time. However, some drug agencies limit their use to 9-12 months. A study evaluating the discontinuation of CGRP mAbs in 65 patients showed that migraine frequency increased after mAbs anti-CGRP interruption. Reinitiation of treatment with CGRP mAbs was also assessed; fortunately, 70% of patients responded to the same mAb they were using before discontinuation. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.